Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Capricor Therapeutics (CAPR): Weighing the Path to the $27 Analyst Target

Capricor Therapeutics (CAPR): Weighing the Path to the $27 Analyst Target

Key Takeaways

  • The central target of $27 is the arithmetic mean of six verified, current analyst price targets, which span roughly $10.50 to $54.
  • At a recent close near $8.30, reaching $27 would require roughly 225% upside — a very large move by any standard.
  • The unusually wide analyst range reflects disagreement over the probability of FDA approval for deramiocel, a binary regulatory catalyst.
  • Supporting factors include positive Phase 3 (HOPE-3) data and the prospect of a first-in-class approved therapy for DMD cardiomyopathy.
  • Key risks include a prior FDA complete response letter (CRL), recurring losses, dilution from capital raises, and heavy short interest.
  • For more detail, explore Major News, Today's Price Move, the Forecast, and upcoming Earnings on additional pages.
  • You can also monitor automated strategies via Trending AI Robots to track shifting technical and momentum conditions.

Analyst Targets: The Wide Range Behind the $27 Consensus

The central target of $27 reflects the mean of six current, individually attributed analyst targets rather than a single firm's view: Roth MKM at about $10.50 (Neutral), B. Riley Securities at $21 (Buy), Piper Sandler at $25 (Buy), Jones at $25 (Buy), Cantor Fitzgerald at $28 (Buy), and Oppenheimer at $54 (Outperform). The mean works out to approximately $27.25, rounded to $27 for readability. The low-to-high spread of roughly $10.50 to $54 is exceptionally wide and mirrors deep disagreement over deramiocel's approval odds. Bullish analysts cite HOPE-3 data and first-in-class positioning; more cautious analysts point to the prior CRL and regulatory uncertainty. Notably, Roth MKM assigns only about 25% odds to approval at the upcoming decision date and 75% odds to a delay or another CRL — a stark contrast with targets in the $50s. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where CAPR Stands Today and the Road to the Target

With a recent close near $8.30, CAPR trades toward the lower end of its 52-week range of roughly $2.96 to $40.37. Reaching $27 implies about 225% upside, categorizing the required move as very large. In practice, any path toward $27 runs through the FDA: approval would likely reprice the shares sharply higher, while a second CRL or another delay would likely pressure them. The stock's December 2025 surge above $40 after positive HOPE-3 results shows how quickly sentiment can shift, but the subsequent retreat into single digits underscores how fragile pre-approval valuations can be.

Factors That Could Support a Move Higher

The core bull case rests on deramiocel becoming the first FDA-approved treatment for DMD cardiomyopathy, a high-unmet-need indication. The Phase 3 HOPE-3 trial met its primary goal, and the company has resubmitted its Biologics License Application (BLA) with an expanded efficacy package. A priority review and the absence of additional clinical-study requirements could support a more constructive valuation. A $150 million public offering completed in December 2025 also strengthened the balance sheet, funding manufacturing and commercialization preparations.

Key Risks That Could Keep the Target Out of Reach

The principal obstacle is regulatory risk. The FDA previously issued a CRL, and Roth MKM views approval at the current decision date as unlikely. The company remains unprofitable — it reported a GAAP net loss of about $40.7 million in the quarter ended June 30, 2026 — and further capital raises could dilute existing holders. High short interest (roughly 35% of float in recent reports) adds volatility, and biotech sector-wide risk appetite can compress valuations quickly. A delay or rejection would undermine the higher end of the target range.

Technical Levels Worth Watching

The shares sit near the bottom of a 52-week range of about $2.96 to $40.37, with the prior spike above $40 acting as a distant overhead reference point. A durable resistance zone is difficult to establish given the volatility, but the $10 area is a nearby psychological level, and a sustained move above it could signal renewed momentum. Support is less well-defined near current levels, with the year's low around $2.96 serving as an extreme downside marker.

Time Horizon and What to Monitor Next

Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary. The decisive near-term event is the FDA decision on deramiocel around the November 22, 2026 PDUFA (Prescription Drug User Fee Act) date. Investors should also watch subsequent analyst rating and target revisions, quarterly cash burn and financing activity, any communication from the FDA about additional data requirements, and broader biotech sentiment. Each of these can meaningfully reshape the probability-weighted outlook behind the $27 mean. From what I see, the binary nature of the catalyst makes ongoing monitoring essential.

Using AI Tools in Volatile Names Like This

I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to help track high-volatility biotech names where sentiment can flip quickly. These AI-driven signals monitor technical behavior and market conditions across thousands of stocks, offering a practical way to surface potential opportunities and adjust positions without relying solely on manual review. It has become a useful part of my routine for names facing binary events like the upcoming FDA decision.

Final Assessment

The question of whether CAPR can reach $27 is ultimately a question about deramiocel's regulatory fate. The $27 central target — the mean of six current analyst targets ranging from about $10.50 to $54 — sits roughly 225% above the recent price, and only approval-oriented outcomes plausibly justify the higher half of that range. The strongest support is the clinical data and an underserved indication; the greatest obstacles are the prior CRL, continued losses, dilution risk, and the binary nature of the upcoming FDA decision. With such a wide spread of analyst views, the target is best read as a weighted view of a highly uncertain outcome rather than a forecast. Investors should monitor the FDA decision, subsequent analyst revisions, and financing developments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CAPR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CAPR in upward trend: price rose above 50-day moving average on November 03, 2026

CAPR moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CAPR as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.

The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 26 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 56 cases where CAPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.592). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (442.120).

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
160
Web
https://www.capricor.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.